Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 16/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197921 | 0.87 | GRM5 (0.77) | GRM5KCNH2CYP1A2CHRNB2CHRNA5 | |
| SCHEMBL4195467 | 0.86 | GRM5 (0.90) | GRM5KCNH2CYP1A2CHRNB2CHRNA5 | |
| SCHEMBL4186575 | 0.84 | GRM5 (0.76) | GRM5KCNH2NPC1MAPT | |
| SCHEMBL4197876 | 0.84 | GRM5 (0.72) | GRM5KCNH2CYP1A2S1PR1 | |
| SCHEMBL29520397 | 0.84 | GRM5 (1.00) | GRM5KCNH2CYP1A2 | |
| SCHEMBL2027395 | 0.84 | GRM5 (1.00) | GRM5KCNH2CYP1A2 | |
| SCHEMBL4186389 | 0.83 | GRM5 (0.73) | GRM5KCNH2NPC1ALDH1A1MAPT | |
| SCHEMBL4189699 | 0.83 | GRM5 (0.80) | GRM5KCNH2CYP1A2NPC1 | |
| SCHEMBL4190018 | 0.82 | GRM5 (0.72) | GRM5KCNH2NPC1S1PR1 | |
| SCHEMBL4193172 | 0.82 | GRM5 (0.71) | GRM5KCNH2CYP1A2CHRNB2CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054491-A1 | Use | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-1513525-B1 | USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GERD | ASTRAZENECA AB (SE) | 2008-05-14 | — | — | EP | claimed |
| EP-1896011-A1 | NEW USE | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | claimed |
| US-20070203163-A1 | Novel Treatment Of Irritable Bowel Syndrome 1 | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | claimed |
| US-20070010553-A1 | New use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| WO-2007001973-A1 | NEW USE | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | WO | claimed |
| EP-1694326-A1 | NOVEL TREATMENT OF IRRITABLE BOWEL SYNDROME I | AstraZeneca AB (SE) | 2006-08-30 | — | — | EP | claimed |
| US-20060128760-A1 | Use of mglur5 antagonists for the treatment of gerd | ASTRAZENECA AB | 2006-06-15 | — | — | US | claimed |
| WO-2005060971-A1 | TREATMENT OF REFLUX-RELATED DISEASES | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | claimed |
| WO-2005060965-A1 | NOVEL TREATMENT OF IRRITABLE BOWEL SYNDROME I | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | claimed |
| EP-1513525-A1 | USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GERD | AstraZeneca AB (SE) | 2005-03-16 | — | — | EP | claimed |
| WO-2004000316-A1 | USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GERD | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | claimed |
| EP-2672971-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | Pharmalundensis AB (SE) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012108831-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | REDECO CHEM AB (SE) | 2012-08-16 | — | — | WO | disclosed |
| US-7964609-B2 | Use of mGluR5 antagonists for the treatment of gerd | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964609-B2 | Use of mGluR5 antagonists for the treatment of gerd | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| WO-2004000316-A1 | USE OF MGLUR5 ANTAGONISTS FOR THE TREATMENT OF GERD | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054491-A1 | Use | FABP6, SLC10A2, GPR119 | GRM5 582/4885KCNH2 3309/4885CYP1A2 30/4885 |
| US-20060128760-A1 | Use of mglur5 antagonists for the treatment of gerd | GRM5, GRIK5, GRM1 | GRM5 1/4885KCNH2 905/4885CYP1A2 3358/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | GRM5 8/4885KCNH2 860/4885CYP1A2 4298/4885 |
| US-20070010553-A1 | New use | GRM5, GRM3, GRM1 | GRM5 1/4885KCNH2 693/4885CYP1A2 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.